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them. Further evaluation is needed to determine the safety
of long-term use.
GASTROINTESTINAL DISEASES/DISORDERS—
Economics Outcomes Presentations
PGI3
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UTILIZATION PATTERNS ON
GASTROESOPHAGEAL REFLUX 
DISEASE-RELATED COSTS
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OBJECTIVE: To determine proton pump inhibitor (PPI)
treatment patterns and their affect on gastroesophageal
reﬂux disease-related costs.
METHODS: This study used claims data to identify 
continuously enrolled GERD-diagnosed subjects newly
treated with a proton pump inhibitor (PPI) between
October 1, 1999 and March 31, 2000. Data were ana-
lyzed for six months following PPI initiation. Results were
stratiﬁed by ﬁrst PPI ﬁlled during the study period. Com-
pliance (measured by possession ratio), dosage escalation
(>25% of initial dose), and daily average consumption
(DACON) were measured. Subjects were assigned to one
of four GERD severity groups based on ICD-9 diagnosis
codes. Regression analysis was performed on GERD-
related costs using treatment patterns and type of PPI
drug as covariates of interest. Confounders including
GERD severity were controlled for in the analysis.
RESULTS: Of 75,452 subjects, there were 51,232
(67.9%) lansoprazole, 22,829 (30.3%) omeprazole and
1,391 (1.8%) rabeprazole subjects. Possession ratio was
not signiﬁcantly different by drug. Only 3.5% of rabepra-
zole subjects escalated versus 5.5% of omeprazole 
subjects and 9.3% of lansoprazole subjects (p = 0.0001).
Among subjects with esophageal ulcer or hiatal hernia,
rabeprazole users had a signiﬁcantly lower ﬁnal DACON
(1.03) versus both lansoprazole (1.20) and omeprazole
subjects (1.22, p = 0.0299). From the regression models,
subjects who were compliant with therapy (ratio ≥ 0.80)
had 43% higher GERD-related pharmacy costs and 33%
higher GERD-related total costs (both p < 0.001). GERD-
related medical costs were not signiﬁcantly affected by
compliance. Subjects who ﬁlled lansoprazole had 9.4%
higher GERD-related pharmacy costs versus rabeprazole
subjects (p < 0.01). Omeprazole subjects had 12.5%
higher GERD-related total costs versus rabeprazole sub-
jects (p < 0.01), while lansoprazole subjects had 18%
higher GERD-related total costs versus rabeprazole 
subjects (p < .001).
CONCLUSIONS: Rabeprazole subjects had lower
GERD-related costs, less escalation and lower DACON
compared to lansoprazole and omeprazole subjects. Com-
pliance was not signiﬁcantly different between drugs, nor
did it decrease GERD-related costs.
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OBJECTIVES: Recent clinical studies report lower 30-
day rebleeding rates associated with the use of intra-
venous proton pump inhibitors (IV PPIs) for treatment of
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